ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg may be appropriate for any patient with persistent diabetic macular edema (DME)

Consider ILUVIEN for the following patients with DME:

Consider ILUVIEN for your patients with persistent DME who have good visual acuity (VA) with prior treatment

In the real-world USER Study, 42% of ILUVIEN-treated eyes had VA 20/40 or better at the time of treatment1

In these eyes, treatment with ILUVIEN maintained VA with 87% fewer DME treatments on average1

USER data: VA and DME treatment frequency before and after ILUVIEN in patients
with VA 20/40 or better at the time of treatment (n = 67 eyes)1,a

aMean follow-up after ILUVIEN across the total USER population (N = 160) was 403 days, with 102 eyes followed up for 6 months, 92 for 12 months, and 88 for 15 months. The number of patients available for follow-up at each time point varied.
bP<0.001 vs treatment frequency before ILUVIEN.

Real-world data from the USER Study confirm the efficacy
of ILUVIEN in a variety of patients with persistent DME.

PATIENTcase study
case study

See why Dr. McCluskey chose ILUVIEN to treat
a patient with persistent DME and 20/40 VA.